Fredrikson & Byron Represents Omnis Pharmaceuticals in its Licensing Agreement with AstraZeneca

January 13, 2015

Fredrikson & Byron acted as legal counsel to Omnis Pharmaceuticals (Omnis), a privately-held biotechnology company focused on the development of oncolytic viruses, in a licensing agreement that will allow AstraZeneca’s global biologics research and development arm, MedImmune, to develop and, if successful, to commercialize Omnis’s lead oncolytic virus program. Fredrikson’s legal team included Ann M. Ladd and Ryan C. Brauer.

Read the news release.